In vitro-in vivo discordance with humanized piperacillin-tazobactam exposures against piperacillin-tazobactam-resistant/pan-β-lactam-susceptible Klebsiella pneumoniae strains

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 7, 2017, Pages

  Stainton, S M ^a   Monogue, M L ^a   Nicolau, D P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Antibiotic resistance; Klebsiella pneumoniae; Piperacillin tazobactam

Indexed keywords

CYCLOPHOSPHAMIDE; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN;

EID: 85022097105     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00491-17     Document Type: Article

References (16)

1. Thabit AK, Crandon JL, Nicolau DP. 2015. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother 16:159–177. https://doi.org/10.1517/14656566.2015.993381.
2. Sutherland CA, Nicolau DP. 2015. Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals. Clin Ther 37:1564–1571. https://doi.org/10.1016/j.clinthera.2015.05.501.
3. Monogue ML, Nicolau DP. 2016. In vitro-in vivo discordance with humanized piperacillin-tazobactam exposures against piperacillin-tazobactam-resistant/pan-β-lactam-susceptible Escherichia coli. Antimicrob Agents Chemother 60:7527–7529. https://doi.org/10.1128/AAC.01208-16.
4. Mediavilla JR, Schneider Z, Nwaigwe C, Chavda K, Chen L, Satlin M, Jenkins SG, Nicolau DP, Kreiswirth BN. 2015. Molecular characterization of cephalosporin/carbapenem/monobactam susceptible but piperacillin-tazobactam (TZP) resistant E. coli. ID Week, abstr 1181.
5. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. 2012. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse Gram-negative organisms. Antimicrob Agents Chemother 56:544 –549. https://doi.org/10.1128/AAC.01752-10.
7. Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. 2002. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375g q4hr and 4.5g q6hr. Chemotherapy 48:59–63. https://doi.org/10.1159/000057663.
8. Beam TR. 1983. Recent developments in antimicrobial therapy with beta-lactam antibiotics. J Med 14:307–336.
9. Komuro M, Kakuo H, Matsushita H, Shimada J. 1994. Inhibition of the renal excretion of tazobactam by piperacillin. J Antimicrob Chemother 34:555–564. https://doi.org/10.1093/jac/34.4.555.
10. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–12. https://doi.org/10.1086/516284.
11. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. 2010. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamics model. Antimicrob Agents Chemother 54: 804–810. https://doi.org/10.1128/AAC.01190-09.
12. Bulik CC, Nicolau DP. 2010. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 54: 4112–4115. https://doi.org/10.1128/AAC.00026-10.
13. Bulik CC, Nicolau DP. 2011. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 55:3002–3004. https://doi.org/10.1128/AAC.01420-10.
14. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother 56: 6137– 6146. https://doi.org/10.1128/AAC.00851-12.
15. Coleman K, Levasseur P, Girard AM, Borgonovi M, Miossec C, Merdjan H, Drusano G, Shlaes D, Nichols WW. 2014. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother 58:3366–3372. https://doi.org/10.1128/AAC.00080-14.
16. Göttig S, Riedel-Christ S, Saleh A, Kempf VA, Hamprecht A. 2016. Impact of blaNDM-1 on fitness and pathogenicity of Escherichia coli and Klebsiella pneumoniae. Int J Antimicrob Agents 47:430–435. https://doi.org/10.1016/j.ijantimicag.2016.02.019.